中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2011年
8期
657-660
,共4页
杜艳萍%江兴堂%尹小文%袁亚婷
杜豔萍%江興堂%尹小文%袁亞婷
두염평%강흥당%윤소문%원아정
癌,非小细胞肺%受体,表皮生长因子%DNA突变分析
癌,非小細胞肺%受體,錶皮生長因子%DNA突變分析
암,비소세포폐%수체,표피생장인자%DNA돌변분석
Carcinoma,non-small-cell lung%Receptor,epidermal growth factor%DNA mutational analysis
目的 探讨表皮生长因子受体(EGFR)基因突变在晚期非小细胞肺癌(NSCLC)二线治疗中的指导意义.方法 对2005年12月至2009年12月住我院的139例既往至少接受过1次含铂化疗且最近1次化疗后肿瘤进展或复发的NSCLC的病理组织行EGFR基因检测,根据检测的结果把患者分为EGFR突变型口服吉非替尼组(31例)和EGFR野生型口服吉非替尼组(50例)及EGFR野生型口服吉非替尼组(50例).对3组患者进行临床特征、病理、疗效、生存期、体力状况评分(PS)、毒副反应及生活质量的分析.结果 女性、腺癌、非吸烟者的EGFR突变率高于对应组;突变型吉非替尼组、野生型吉非替尼组(62.0%,31例)和野生型多烯紫杉醇组中位无进展生存期(分别为2.8、2.0和2.5个月)、中位生存时间(分别为8.9、7.1和7.8个月)比较,差异有统计学意义(H值分别为11.198、16.991,均P＜0.01).突变型吉非替尼组、野生型吉非替尼组PS评分的变化分别为96.8%(30例)和62.0%(31例),差异有统计学意义(x2=12.583,P＜0.01).野生型吉非替尼组(62.0%,31例)和野生型多烯紫杉醇组(66.0%,33例)化疗PS评分变化比较,差异无统计学意义(x2=0.878,P＞0.05).结论 表皮生长因子受体基因突变可作为指导晚期NSCLC二线治疗的重要指标.
目的 探討錶皮生長因子受體(EGFR)基因突變在晚期非小細胞肺癌(NSCLC)二線治療中的指導意義.方法 對2005年12月至2009年12月住我院的139例既往至少接受過1次含鉑化療且最近1次化療後腫瘤進展或複髮的NSCLC的病理組織行EGFR基因檢測,根據檢測的結果把患者分為EGFR突變型口服吉非替尼組(31例)和EGFR野生型口服吉非替尼組(50例)及EGFR野生型口服吉非替尼組(50例).對3組患者進行臨床特徵、病理、療效、生存期、體力狀況評分(PS)、毒副反應及生活質量的分析.結果 女性、腺癌、非吸煙者的EGFR突變率高于對應組;突變型吉非替尼組、野生型吉非替尼組(62.0%,31例)和野生型多烯紫杉醇組中位無進展生存期(分彆為2.8、2.0和2.5箇月)、中位生存時間(分彆為8.9、7.1和7.8箇月)比較,差異有統計學意義(H值分彆為11.198、16.991,均P＜0.01).突變型吉非替尼組、野生型吉非替尼組PS評分的變化分彆為96.8%(30例)和62.0%(31例),差異有統計學意義(x2=12.583,P＜0.01).野生型吉非替尼組(62.0%,31例)和野生型多烯紫杉醇組(66.0%,33例)化療PS評分變化比較,差異無統計學意義(x2=0.878,P＞0.05).結論 錶皮生長因子受體基因突變可作為指導晚期NSCLC二線治療的重要指標.
목적 탐토표피생장인자수체(EGFR)기인돌변재만기비소세포폐암(NSCLC)이선치료중적지도의의.방법 대2005년12월지2009년12월주아원적139례기왕지소접수과1차함박화료차최근1차화료후종류진전혹복발적NSCLC적병리조직행EGFR기인검측,근거검측적결과파환자분위EGFR돌변형구복길비체니조(31례)화EGFR야생형구복길비체니조(50례)급EGFR야생형구복길비체니조(50례).대3조환자진행림상특정、병리、료효、생존기、체력상황평분(PS)、독부반응급생활질량적분석.결과 녀성、선암、비흡연자적EGFR돌변솔고우대응조;돌변형길비체니조、야생형길비체니조(62.0%,31례)화야생형다희자삼순조중위무진전생존기(분별위2.8、2.0화2.5개월)、중위생존시간(분별위8.9、7.1화7.8개월)비교,차이유통계학의의(H치분별위11.198、16.991,균P＜0.01).돌변형길비체니조、야생형길비체니조PS평분적변화분별위96.8%(30례)화62.0%(31례),차이유통계학의의(x2=12.583,P＜0.01).야생형길비체니조(62.0%,31례)화야생형다희자삼순조(66.0%,33례)화료PS평분변화비교,차이무통계학의의(x2=0.878,P＞0.05).결론 표피생장인자수체기인돌변가작위지도만기NSCLC이선치료적중요지표.
Objective To explore the effect of gene mutations of epidermal growth factor receptor ( EGFR) on targeting therapy of advanced non-small cell lung cancer (NSCLC). Methods The 139 hospitalized patients who had been treated at least once with platinum-based chemotherapy and had tumor progression or recurrence after the last chemotherapy between December 2005 and December 2009, underwent EGFR gene test extracted from the pathological tissues. Based on the results of the test, the patients were divided into three groups: EGFR mutation per os (p.o.)Gefitinib (MPG) group, wild-type EGFR per os (p. o. ) Gefitinib (WpG) group and wild-type EGFR post-docetaxel chemotherapy (WpD) group. Clinical characteristics, pathology, treatment efficacy,survival time, performance status (PS) score, adverse reaction and quality of life of patients in the three groups were assessed. Results The EGFR mutation rate were higher in female, patients with adenocarcinoma and non-smokers than in male, smokers and those without adenocarcinoma. There were significant differences in median progression-free survival and median survival time among the three groups, which were 2.8 and 8. 9 months in MpG group, 2.0 and 7.1 months in WpG group,2.5 and 7. 8 months in WpD group(H=11. 198, 16. 991 ,all P＜0.01). The changes of PS score were significantly different between MpG group and WpG group (96. 8% vs. 62. 0%, x2 = 12. 583 ,P＜0. 01 ). However, there was no difference in changes of PS score between WpG group and WpD group (62. 0% vs. 66. 0%, x2 =0. 878,P＞0. 05). Conclusions The gene mutation of epidermal growth factor receptor may be served as an important indicator of advanced non-small cell cancer therapy.
